Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Lastest Finance News

IN BRIEF: Playtech starts GBP19 million share buyback

27th Mar 2026 09:41

Playtech PLC - Douglas, Isle of Man-based gambling software - Starts on Friday share buyback programme for up to 5.7 million shares, worth about GBP19.0 million at their current market price. Playtech plans to complete the buyback before its next annual general meeting, set to be held towards the end of May. The buyback will be run by US investment bank Jefferies International Ltd. The repurchased shares will be used for future employee share awards. Read More

LONDON BROKER RATINGS: BofA raises Berkeley; UBS raises Savills

27th Mar 2026 09:28

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday day: Read More

Iran holding world's economy "hostage" with Hormuz closure – Cooper

27th Mar 2026 09:27

(Alliance News) - Iran "cannot hold the global economy hostage", UK Foreign Secretary Yvette Cooper said as she met counterparts including Marco Rubio from the US to discuss the Middle East crisis. Read More

Senior agrees to extend Advent takeover offer deadline amid talks

27th Mar 2026 09:26

(Alliance News) - Senior PLC on Friday said it has extended the deadline for a revised takeover offer from Advent International LP. Read More

IN BRIEF: Avacta raises GBP10 million in equity for clinical tests

27th Mar 2026 09:22

Avacta Group PLC - London-based biopharmaceutical company developing a tumour-activated oncology delivery platform - Raises GBP10 million from a placing of and subscription to 15.9 million new shares at 63 pence each. The new shares represent 3.6% of Avacta's total prior to the issuance. Two non-executive directors, Richard Hughes and David Bryant, contribute a total of GBP550,000 to the raise. The share offer is run by Zeus Capital as broker and bookrunner. Zeus will receive warrants over 4.4 million new shares at the same 63p price, exercisable over five years. The raise is in line with the plan announced after the London market close on Thursday. The fresh cash will be used to progress Avacta's research and development programmes into early in the first quarter of 2027, providing enough cash to get to initial data from a phase 1a trial of AVA6103, its second clinical program. AVA6103, a peptide drug conjugate. Read More

Nearly half a million Lloyds customers hit by data breach after glitch

27th Mar 2026 09:10

(Alliance News) - Lloyds Banking Group PLC has paid out compensation after nearly half a million people were impacted by an IT glitch exposing the personal data of customers earlier this month. Read More

LONDON MARKET OPEN: Stocks mixed as Brent oil nears USD110

27th Mar 2026 09:04

(Alliance News) - Stock prices in London opened mixed on Friday, with the FTSE 100 edging higher despite continued uncertainty regarding Iran peace talks and muted sentiment across European markets. Read More

BASF lowers stake in Harbour Energy to 35% after upsized placing

27th Mar 2026 08:58

(Alliance News) - BASF SE on Friday said it has reduced its shareholding in Harbour Energy PLC, acquired as part of the Wintershall Dea deal, selling a 6.5% stake to cut its holding to 35% from 41.5%. Read More

European Medicine Agency to review GSK's chronic hepatitis B treatment

27th Mar 2026 08:38

(Alliance News) - GSK PLC on Friday said the European Medicines Agency has accepted for review its investigational chronic hepatitis B treatment, bepirovirsen. Read More

AstraZeneca hails positive results in tozorakimab lung disease trials

27th Mar 2026 08:26

(Alliance News) - AstraZeneca PLC on Friday reported positive phase-three trial results for its chronic obstructive pulmonary disease treatment tozorakimab. Read More

IN BRIEF: Metlen delays release of 2025 results to complete audit

27th Mar 2026 08:14

Metlen Energy & Metals PLC - Athens-based energy and metallurgy company - Says external auditors PricewaterhouseCoopers LLP and PricewaterhouseCoopers SA request more time to complete work on its 2025 financial statement, Metlen's first as a dual-listed entity in London and Athens. Metlen will now release of its annual results on April 9 after a nine-day delay. It confirms guidance of earnings before interest, tax, depreciation and amortisation of around GBP750 million. Read More

LONDON BRIEFING: UK retail sales fall; GSK drug accepted for review

27th Mar 2026 07:56

(Alliance News) - UK retail sales fell in the month of February but by less than expected, while GSK and AstraZeneca hailed positive clinical and regulatory progress. Herald Investment Trust said it will proceed with a backstop tender offer for up to 100% of shares if no agreement is reached with Saba. Read More

Autotrader among firms under investigation in UK over online reviews

27th Mar 2026 07:49

(Alliance News) - Food delivery company Just Eat, funeral firm Dignity and motor platform Autotrader Group PLC are among five firms under investigation by the UK's competition watchdog as part of its crackdown on fake and misleading online reviews. Read More

UK retail sales fall in February but decline less than expected

27th Mar 2026 07:13

(Alliance News) - UK retail sales volumes fell in February after a strong start to the year, though sales remained higher over the three months, official data showed Friday. Read More

IN BRIEF: Faron Pharmaceuticals hires Heikki Jouttijarvi as CTO

27th Mar 2026 07:00

Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Hires Heikki Jouttijarvi as chief technical officer, saying he has decades of experience in biopharma manufacturing, supply chain management and commercial operations. Chief Executive Officer Juho Jalkanen says: "His wealth of experience with commercial operations, manufacturing and supply chain management with late-stage and approved drugs is incredibly valuable for us as we progress with bexmarilimab to the announced phase IIb trial in higher-risk myelodysplastic syndromes". Bexmarilimab is an investigational immunotherapy designed to overcome resistance to existing treatments, among others. Myelodysplastic syndromes are a type of blood cancer. Read More

789101112131415
FTSE 100 Latest
Value10,176.45
Change48.49